Enterprise Value

7.203B

Cash

846.3M

Avg Qtr Burn

-91.76M

Short % of Float

9.14%

Insider Ownership

15.33%

Institutional Own.

85.29%

Qtr Updated

03/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Tavapadon (adjunct with L-Dopa) Details
Parkinson's disease, Brain disease

Phase 3

Data readout

Tavapadon Details
Parkinson's disease, Brain disease

Phase 3

Data readout

Phase 2

Data readout

Darigabat Details
Social Anxiety Disorder, Panic Disorder

Phase 2

Data readout

Emraclidine (CVL-231) Details
Brain disease, Schizophrenia

Phase 2

Data readout

Phase 2

Data readout

Emraclidine (CVL-231) Details
Brain disease, Neurodegenerative disease, Alzheimer's disease

Phase 1

Data readout

CVL-354 Details
Major depressive disorder

Phase 1

Data readout